The domestic launch of the stomach cancer target agent ‘Cyramza’ is visualized
The fact that a new target agent for stomach cancer is visualized attracted the pharmaceutical industry.
According to the Ministry of Food and Drug Safety on the 15th, the Lilly Korea’s stomach cancer target agent ‘Cyramza(ramucirumab)’ has been approved.
Cyramza can be used as a solo therapy a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
